Welch & Forbes LLC Sells 660 Shares of Eli Lilly and Co (LLY)

Welch & Forbes LLC lowered its stake in shares of Eli Lilly and Co (NYSE:LLY) by 0.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 144,660 shares of the company’s stock after selling 660 shares during the period. Welch & Forbes LLC’s holdings in Eli Lilly and were worth $12,168,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the stock. Capital Advisors Inc. OK raised its stake in shares of Eli Lilly and by 28.4% in the first quarter. Capital Advisors Inc. OK now owns 3,711 shares of the company’s stock valued at $312,000 after buying an additional 820 shares during the period. Whittier Trust Co. raised its stake in shares of Eli Lilly and by 37.9% in the first quarter. Whittier Trust Co. now owns 10,970 shares of the company’s stock valued at $923,000 after buying an additional 3,014 shares during the period. First Merchants Corp raised its stake in shares of Eli Lilly and by 11.5% in the first quarter. First Merchants Corp now owns 32,533 shares of the company’s stock valued at $2,736,000 after buying an additional 3,367 shares during the period. Moloney Securities Asset Management LLC acquired a new stake in shares of Eli Lilly and during the first quarter valued at about $202,000. Finally, Oakworth Capital Inc. raised its stake in shares of Eli Lilly and by 18.0% in the first quarter. Oakworth Capital Inc. now owns 6,694 shares of the company’s stock valued at $563,000 after buying an additional 1,019 shares during the period. Institutional investors own 75.15% of the company’s stock.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Shares of Eli Lilly and Co (NYSE:LLY) traded up 0.49% during trading on Thursday, hitting $78.34. 1,737,281 shares of the company were exchanged. The firm’s 50-day moving average price is $81.62 and its 200 day moving average price is $78.35. The firm has a market capitalization of $82.75 billion, a PE ratio of 37.88 and a beta of 0.30. Eli Lilly and Co has a 12 month low of $64.18 and a 12 month high of $86.72.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, April 25th. The company reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.96 by $0.02. Eli Lilly and had a net margin of 12.90% and a return on equity of 24.74%. The firm had revenue of $5.23 billion for the quarter, compared to analysts’ expectations of $5.22 billion. During the same quarter last year, the company earned $0.83 EPS. The firm’s revenue for the quarter was up 7.5% compared to the same quarter last year. On average, equities research analysts expect that Eli Lilly and Co will post $4.12 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, June 9th. Investors of record on Monday, May 15th will be paid a $0.52 dividend. The ex-dividend date of this dividend is Thursday, May 11th. This represents a $2.08 dividend on an annualized basis and a yield of 2.66%. Eli Lilly and’s dividend payout ratio is currently 80.62%.

COPYRIGHT VIOLATION WARNING: This story was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://sportsperspectives.com/2017/05/25/welch-forbes-llc-sells-660-shares-of-eli-lilly-and-co-lly.html.

Several brokerages recently issued reports on LLY. Sanford C. Bernstein restated an “outperform” rating and set a $88.00 target price on shares of Eli Lilly and in a research report on Sunday. Goldman Sachs Group Inc restated a “buy” rating and set a $92.00 target price on shares of Eli Lilly and in a research report on Tuesday, May 16th. BMO Capital Markets restated an “underperform” rating and set a $73.00 target price (up from $71.00) on shares of Eli Lilly and in a research report on Saturday, April 29th. Jefferies Group LLC restated a “buy” rating and set a $92.00 target price (down from $94.00) on shares of Eli Lilly and in a research report on Saturday, April 29th. Finally, Argus lowered shares of Eli Lilly and from a “buy” rating to a “hold” rating and boosted their target price for the company from $64.18 to $81.00 in a research report on Thursday, April 27th. They noted that the move was a valuation call. Two analysts have rated the stock with a sell rating, five have given a hold rating and thirteen have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $87.59.

In other Eli Lilly and news, SVP Enrique A. Conterno sold 25,000 shares of Eli Lilly and stock in a transaction on Thursday, May 4th. The shares were sold at an average price of $82.76, for a total transaction of $2,069,000.00. Following the sale, the senior vice president now owns 114,217 shares of the company’s stock, valued at approximately $9,452,598.92. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of Eli Lilly and stock in a transaction on Thursday, March 30th. The stock was sold at an average price of $84.67, for a total transaction of $17,780,700.00. Following the sale, the insider now directly owns 124,690,804 shares in the company, valued at approximately $10,557,570,374.68. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by company insiders.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

12 Month Chart for NYSE:LLY

Receive News & Ratings for Eli Lilly and Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply